Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SARS-CoV-2 Cellular and Humoral Immune Response Following Vaccination of Kidney Transplant Recipients and Healthy Controls

NCT04747522 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04747522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04747522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SARS-CoV-2 Cellular and Humoral Immune Response Following Vaccination of Kidney Transplant Recipients and Healthy Controls
Lead sponsor
Oslo University Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 22, 2021
Completion date
December 31, 2024
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant infection, sars-cov infection